Gene editing is radically changing the landscape for drug discovery and development. Whether it be via: deploying precisely engineered human disease models in whole-genome genetic screens to identify novel drug targets; generation of cell lines capable of high-yield low-cost manufacturing of biological drugs; or the development of gene and cell therapy approaches that promise individual patient cures for diseases such as cancer, cystic fibrosis, and Parkinson’s disease, these ground-breaking technologies are allowing researchers an unprecedented ability to address some of biology’s most challenging questions.
On March 15th, 2016 Horizon hosted a roundtable event on gene editing and its impact on basic genomics research and the advance of personalised medicine at the Science Museum in London, where some of the foremost innovators in the fields of gene editing (including CRISPR, rAAV and ZFN) met to discuss trends and innovations in the field and to look at real world applications of this new technology.
We were able to record the event, and below you will find the presentations and Q and A sessions, along with a set of brief animations on the CRISPR rAAV approaches to gene editing and an overview of Horizon’s CRISPR-based capabilities.
Designing, engineering and applying gene-edited cells to advance human health
Dr. Darrin Disley, Chief Executive Officer and President Research Biotech, Horizon Discovery Group plc
An introduction to gene editing technologies
Dr. Eric Hendrickson, Professor, Biochemistry, Molecular Biology and Biophysics, University of Minnesota and expert in gene manipulation using CRISPR rAAV, ZFN and TALEN
Applications of gene editing in research
Dr. Sebastian Nijman, Associate Member of the Ludwig Institute for Cancer Research in Oxford, Director of Functional Genomics at the Target Discovery Institute and adjunct Principal Investigator at the Research Center for Molecular Medicine (CeMM)
Applications of CRISPR gene editing in drug discovery and development
Dr. Feng Zhang, Professor of Biomedical Engineering, MIT, Core Member of the Broad Institute and co-inventor of CRISPR gene editing
The impact of gene editing on therapeutic development and clinical diagnostics
Dr. Jon Moore, Chief Scientific Officer and VP Research Biotech, Horizon Discovery Group plc.